drugset / Trial / NCT07146919
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
Non-randomizedSequentialOpen-labelTreatment
Summary
The aim of this study is to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of bemarituzimab given in combination with a fixed dose of bevacizumab and to assess the clinical activity of the proposed combination bemarituzumab and bevacizumab in 3 parallel and independent cohorts of gynecological cancer (endometrium, ovary and cervix).
Timeline
- Start
- 2025-10-15
- Primary completion
- 2030-10-15
- Completion
- 2030-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemarituzumab | Monoclonal antibody | 11 mg/kg | Intravenous |
| Subject | Bemarituzumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Bemarituzumab | Monoclonal antibody | 22 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |